Dr. Rabih C. Fahed, MD

Dr. Fahed practices at Hematology & Oncology Consultants in Norfolk, Nebraska.

Dr. Fahed's NPI, 1043488844, was assigned on February 14, 2008. Dr. Fahed holds Nebraska license 24944.

Dr. Fahed's primary practice is Hematology & Oncology Consultants, at 110 N 29th N St, Norfolk, NE 68701 in Madison County. The practice phone is (402) 572-3535.

Dr. Fahed's primary practice is Hematology & Oncology Consultants in Norfolk, Nebraska. Dr. Fahed is also affiliated with Faith Regional Health Services. The medical group on file is Hematology & Oncology Consultants, P.C. Dmand AI also links Dr. Fahed to 4 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fahed practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Fahed's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Fahed is licensed in Nebraska.

CMS data shows 128,841 Medicare services from Dr. Fahed across 47 procedure codes in 2024, for 847 Medicare patients. Medicare paid $1,577,141 for them. Every service was in an office.

CMS counts 847 Medicare patients who saw Dr. Fahed in 2024. The largest group is 65 to 74, with 394 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fahed's median patient age at 71, with 56% women.

In 2024, Dr. Fahed wrote 2,118 Medicare Part D claims for 348 patients. 77% of them were for generic drugs. CMS names the drug for 1,924 of them, across 34 drugs with 11 or more claims each, at $3,556,075 in total drug cost. In 2023, CMS named 1,664 claims across 34 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Fahed for performance year 2024, reported individually. Dr. Fahed accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 2 papers to Dr. Fahed, published from 2019 to 2022. Dr. Fahed's most frequent co-authors are Enas Al Zaghal, MD, Punya Hari Dahal, MD and Ruby Anne Deveras, MD.

Dmand AI links Dr. Fahed to 2 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck and Breast Diseases. University of Nebraska sponsors the most, 2.

CMS Open Payments shows 918 general payments to Dr. Fahed from 69 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 63% of the total. Bristol-Myers Squibb Company paid the most, $182,582.